Nifty Pharma index set to post biggest weekly rally in 15 years

At 11:23 am; Nifty Pharma index, the largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week.

Aurobindo Pharma wrests second position among drug firms from Lupin
Aurobindo Pharma
SI Reporter Mumbai
Last Updated : Jun 15 2018 | 12:22 PM IST
Shares of pharmaceutical companies are on a roll with the Nifty Pharma index all set to post its biggest weekly gain in 15 years following the positive news flow from the corporate levels with regard to regulatory issues.

At 11:23 am; the Nifty Pharma index -- largest gainer among sectoral indices, was up 2.2% at 9,310, surging 8.2% thus far in current week. Earlier, in week ended August 31, 2003, the index had recorded 9.1% gain.

Nifty Pharma  index was quoting higher for the eight straight trading days on the National Stock Exchange (NSE). During the period, the pharma index rallied 15% as compared to 2% rise in the benchmark Nifty 50 index.

Dr Reddy’s Laboratories, Lupin, Cadila Healthcare, Sun Pharmaceutical Industries, Aurobindo Pharma and Cipla from the Nifty Pharma index were up in the range of 8% to 14% thus far in the current week. Alembic Pharmaceuticals, Granules India, Marksans Pharma, Ajanta Pharma and Suven Lifesciences, the non-index pharma gained between 9% and 20% during the week.

Dr Reddy’s Labs was up 4% to Rs 2,365 today, after the U.S. Food and Drug Administration (USFDA) approved the first generic versions of Indivior’s Suboxone sublingual film for the treatment of opioid dependence. The stock rallied 14% so far in current week.

Lupin gained 3% at Rs 923, too rallied 14% in past five trading sessions. The company on Thursday it has received approval from the US health regulator to market Drospirenone, Ethinyl Estradiol, Levomefolate Calcium tablets, used to prevent pregnancy, in the American market.

While, during the week, Sun Pharma announced the resolution of regulatory compliance issues at Halol plant, Aurobindo Pharma gained on the back of US FDA (Food and Drug Administration) approval for Omeprazole (used to treat certain stomach and esophagus problems). Both these stocks have gained 8% so far in current week.

COMPANY LATEST 1-WEEK BEFORE GAIN(%)
ALEMBIC PHARMA 523.55 435.25 20.29
DR REDDY'S LABS 2358.25 2062.90 14.32
LUPIN 920.50 810.05 13.63
GRANULES INDIA 89.10 78.80 13.07
MARKSANS PHARMA 31.50 27.95 12.70
AJANTA PHARMA 1082.80 976.35 10.90
CADILA HEALTH. 400.75 364.35 9.99
SUVEN LIFE SCIE. 235.20 214.70 9.55
AUROBINDO PHARMA 620.25 572.35 8.37
SUN PHARMA.INDS. 572.00 528.25 8.28
CIPLA 604.75 559.65 8.06
BLISS GVS PHARMA 187.50 173.65 7.98
WOCKHARDT 743.00 689.30 7.79
GLENMARK PHARMA. 597.50 556.75 7.32
DISHMAN CARBOGEN 317.00 295.50 7.28
STRIDES SHASUN 380.50 357.55 6.42
GLAXOSMI. PHARMA 2787.05 2629.90 5.98

One subscription. Two world-class reads.

Already subscribed? Log in

Subscribe to read the full story →
*Subscribe to Business Standard digital and get complimentary access to The New York Times

Smart Quarterly

₹900

3 Months

₹300/Month

SAVE 25%

Smart Essential

₹2,700

1 Year

₹225/Month

SAVE 46%
*Complimentary New York Times access for the 2nd year will be given after 12 months

Super Saver

₹3,900

2 Years

₹162/Month

Subscribe

Renews automatically, cancel anytime

Here’s what’s included in our digital subscription plans

Exclusive premium stories online

  • Over 30 premium stories daily, handpicked by our editors

Complimentary Access to The New York Times

  • News, Games, Cooking, Audio, Wirecutter & The Athletic

Business Standard Epaper

  • Digital replica of our daily newspaper — with options to read, save, and share

Curated Newsletters

  • Insights on markets, finance, politics, tech, and more delivered to your inbox

Market Analysis & Investment Insights

  • In-depth market analysis & insights with access to The Smart Investor

Archives

  • Repository of articles and publications dating back to 1997

Ad-free Reading

  • Uninterrupted reading experience with no advertisements

Seamless Access Across All Devices

  • Access Business Standard across devices — mobile, tablet, or PC, via web or app

Next Story